Screener
Wave Life Sciences WVE CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating lease liabilities | (4,191) | (3,693) |
| Net cash used in operating activities | (113,135) | (109,051) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (1,322) | (471) |
| Purchases of marketable securities | (122,570) | — |
| Net cash used in investing activities | (123,892) | (471) |
| Cash flows from financing activities | ||
| Proceeds from issuance of ordinary shares pursuant to the “at-the-market” equity program, net of offering costs | — | 12,361 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's capex?
- Wave Life Sciences (WVE) reported capex of $884K in Q2 2026.
- How has Wave Life Sciences's capex changed year-over-year?
- Wave Life Sciences's capex increased by 188.9% year-over-year, from $306K to $884K.
- What is the long-term trend for Wave Life Sciences's capex?
- Over 4 years (2021 to 2025), Wave Life Sciences's capex has grown at a 6.4% compound annual growth rate (CAGR), from $560K to $719K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Wave Life Sciences's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude